Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Post by Time4TAon Jun 01, 2011 7:16am
266 Views
Post# 18654323

Shares represent some Very Good Value Here

Shares represent some Very Good Value HereLast Financing was performed  by Insiders @
.18. The company raised a total of $9.687,233 . It was a Rights offering...in a very Tough market a few Months after that BIG Market Meltdown....Money was still able to FLow into BLU...that in itself was pretty amazing in that now many Listed Companies were not able to raise funds. ...but BLU Did.....

Under the rights offering, rights were exercised to subscribe for9,120,177 common shares at the Subscription Price for proceeds of C$1,687,233.Additionally, in accordance with the terms of the stand-by purchase agreementsentered into by BELLUS Health with Vitus Investments III Private Limited("Vitus") and Victoria Square Ventures Inc. ("VSVI"), each of Vitus and VSVIwill subscribe for 21,621,621 common shares of BELLUS Health at theSubscription Price for an aggregate of C$8,000,000.
The rights issue is a special form of shelf offering or shelf registration. With the issued rights, existing shareholders have the privilege to buy a specified number of new shares from the firm

Bullboard Posts